CAR T cell therapy for B-cell lymphomas

Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.

Abstract

B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.

Keywords: Aggressive lymphomas; CART; Diffuse large B cell lymphoma; Immunotherapy; Refractory.

Publication types

  • Review

MeSH terms

  • Antigens, CD19 / immunology*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphoma, Follicular* / immunology
  • Lymphoma, Follicular* / pathology
  • Lymphoma, Follicular* / therapy
  • Lymphoma, Large B-Cell, Diffuse* / immunology
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Multicenter Studies as Topic
  • Receptors, Chimeric Antigen / immunology
  • Receptors, Chimeric Antigen / therapeutic use*
  • Risk Factors

Substances

  • Antigens, CD19
  • CD19 molecule, human
  • Receptors, Chimeric Antigen